Endogenous estrogen levels and the effects of ultra-low-dose transdermal estradiol therapy on bone turnover and BMD in postmenopausal women

Journal of Bone and Mineral Research

Volumn 22, Issue 11, 2007, Pages 1791-1797

  Huang, Alison J ^a,b,g   Ettinger, Bruce ^c   Vittinghoff, Eric ^b   Ensrud, Kristine E ^d   Johnson, Karen C ^e   Cummings, Steven R ^b,f  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DIVISION OF RESEARCH   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^g NONE   (United States)

Author keywords

BMD; Bone turnover; Endogenous estradiol; Estrone; Osteoporosis

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ESTRADIOL; ESTROGEN; OSTEOCALCIN; PLACEBO; SEX HORMONE BINDING GLOBULIN;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESTROGEN BLOOD LEVEL; FEMALE; HIP; HUMAN; IMMUNORADIOMETRIC ASSAY; LOW DRUG DOSE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MENOPAUSAL SYNDROME; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL PATCH; TREATMENT OUTCOME; BLOOD; BONE; BONE REMODELING; DRUG EFFECT; INTRADERMAL DRUG ADMINISTRATION; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RADIOGRAPHY;

ADMINISTRATION, CUTANEOUS; AGED; BONE AND BONES; BONE DENSITY; BONE REMODELING; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE;

EID: 38449089068     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.070707     Document Type: Article

References (33)

1. Pouilles JM, Tremollieres F, Ribot C 1993 The effects of menopause on longitudinal bone loss from the spine. Calcif Tissue Int 52:340-343.
2. Ahlborg HG, Johnell O, Nilsson BE, Jeppsson S, Rannevik G, Karlsson MK 2001 Bone loss in relation to menopause: A prospective study during 16 years. Bone 28:327-331.
3. Nilas L, Christiansen C 1987 Bone mass and its relationship to age and the menopause. J Clin Endocrinol Metab 65:697-702.
4. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645.
5. Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R 2002 Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 87:4470-4475.
6. Yoshimura N, Kasamatsu T, Sakata K, Hashimoto T, Cooper C 2002 The relationship between endogenous estrogen, sex hormone-binding globulin, and bone loss in female residents of a rural Japanese community: The Taiji Study. J Bone Miner Metab 20:303-310.
7. Ongphiphadhanakul B, Chanprasertyothin S, Chailurkit L, Chansirikarn S, Puavilai G, Rajatanavin R 2004 Differential associations of residual estradiol levels with bone mineral density and serum lipids in postmenopausal women with osteoporosis. Maturitas 48:193-196.
8. Lambrinoudaki I, Christodoulakos G, Aravantinos L, Antoniou A, Rizos D, Chondros C, Kountouris A, Chrysofakis G, Creatsas G 2006 Endogenous sex steroids and bone mineral density in healthy Greek postmenopausal women. J Bone Miner Metab 24:65-71.
9. Garcia-Perez MA, Moreno-Mercer J, Tarin JJ, Cano A 2003 Relationship between PTH, sex steroid and bone turnover marker measurements and bone density in recently postmenopausal women. Maturitas 45:67-74.
10. Rapuri PB, Gallagher JC, Haynatzki G 2004 Endogenous levels of serum estradiol and sex hormone binding globulin determine bone mineral density, bone remodeling, the rate of bone loss, and response to treatment with estrogen in elderly women. J Clin Endocrinol Metab 89:4954-4962.
11. Bagur A, Oliveri B, Mautalen C, Belotti M, Mastaglia S, Yankelevich D, Sayegh F, Royer M 2004 Low levels of endogenous estradiol protect bone mineral density in young postmenopausal women. Climacteric 7:181-188.
12. Greendale GA, Edelstein S, Barrett-Connor E 1997 Endogenous sex steroids and bone mineral density in older women and men: The Rancho Bernardo Study. J Bone Miner Res 12:1833-1843.
13. Ettinger B, Pressman A, Sklarin P, Bauer DC, Cauley JA, Cummings SR 1998 Associations between low levels of serum estradiol, bone density, and fractures among elderly women: The study of osteoporotic fractures. J Clin Endocrinol Metab 83:2239-2243.
14. Chapurlat RD, Bauer DC, Cummings SR 2001 Association between endogenous hormones and sex hormone-binding globulin and bone turnover in older women: Study of osteoporotic fractures. Bone 29:381-387.
15. Sypniewska G, Chodakowska-Akolinska G 2000 Bone turnover markers and estradiol level in postmenopausal women. Clin Chem Lab Med 38:1115-1119.
16. Heshmati HM, Khosla S, Robins SP, O'Fallon WM, Melton LJ III, Riggs BL 2002 Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 17:172-178.
17. Stone K, Bauer DC, Black DM, Sklarin P, Ensrud KE, Cummings SR 1998 Hormonal predictors of bone loss in elderly women: A prospective study. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 13:1167-1174.
18. Sowers MR, Jannausch M, McConnell D, Little R, Greendale GA, Finkelstein JS, Neer RM, Johnston J, Ettinger B 2006 Hormone predictors of bone mineral density changes during the menopausal transition. J Clin Endocrinol Metab 91:1261-1267.
19. Chapurlat RD, Garnero P, Breart G, Meunier PJ, Delmas PD 2000 Serum estradiol and sex hormone-binding globulin and the risk of hip fracture in elderly women: The EPIDOS study. J Bone Miner Res 15:1835-1841.
20. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD 2000 Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J Bone Miner Res 15:1526-1536.
21. Goderie-Plomp HW, van der Klift M, de Ronde W, Hofman A, de Jong FH, Pols HA 2004 Endogenous sex hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: The Rotterdam Study. J Clin Endocrinol Metab 89:3261-3269.
22. Sipila S, Heikkinen E, Cheng S, Suominen H, Saari P, Kovanen V, Alen M, Rantanen T 2006 Endogenous hormones, muscle strength, and risk of fall-related fractures in older women. J Gerontol A Biol Sci Med Sci 61:92-96.
23. Ettinger B, Ensrud KE, Wallace R, Johnson KC, Cummings SR, Yankov V, Vittinghoff E, Grady D 2004 Effects of ultra-low-dose transdermal estradiol on bone mineral density: A randomized clinical trial. Obstet Gynecol 104:443-451.
24. Hui SL, Perkins AJ, Zhou L, Longcope C, Econs MJ, Peacock M, McClintock C, Johnston CC Jr 2002 Bone loss at the femoral neck in premenopausal white women: Effects of weight change and sex-hormone levels. J Clin Endocrinol Metab 87:1539-1543.
25. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD 1996 Markers of bone resorption predict hip fracture in elderly women: The EPIDOS Prospective Study. J Bone Miner Res 11:1531-1538.
26. Akesson K, Ljunghall S, Jonsson B, Sernbo I, Johnell O, Gardsell P, Obrant KJ 1995 Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: A retrospective and prospective population-based study of women. J Bone Miner Res 10:1823-1829.
27. Wasnich RD, Miller PD 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231-236.
28. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281-289.
29. Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C 2001 Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12:922-930.
30. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD 2004 Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The fracture intervention trial. J Bone Miner Res 19:1250-1258.
31. Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M, Krueger KA 2002 Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287:216-220.
32. Garnero P, Tsouderos Y, Marton I, Pelissier C, Varin C, Delmas PD 1999 Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women. J Clin Endocrinol Metab 84:2390-2397.
33. Heaney RP, Draper MW 1997 Raloxifene and estrogen: Comparative bone-remodeling kinetics. J Clin Endocrinol Metab 82:3425-3429.